Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2023-07-12 Major Shareholding Noti…
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a mandatory regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (such as block deals and rights offerings), and the purpose of the holding. This falls under the 'Major Shareholding Notification' category.
2023-07-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent filing) where directors or major shareholders report changes in their shareholdings. This falls under the category of 'Director's Dealing' (DIRS) as it details personal share transactions and ownership changes by company insiders.
2023-07-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Director's Dealing' or 'Insider Trading' report) where company executives disclose changes in their shareholdings. It details the specific transactions (block deals, stock option exercises) of a director (Kim Byung-chul) of Clinomics. This fits the 'Director's Dealing' (DIRS) category perfectly.
2023-07-12 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제1회차)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding the 'Acquisition of Convertible Bonds before Maturity'. It details the specific financial transaction where the company repurchased its own convertible bonds. This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of the filing regarding bond acquisition/redemption, it fits best under the Capital/Financing Update category.
2023-07-07 Korean
유상증자1차발행가액결정
Capital/Financing Update Classification · 1% confidence The document is an official announcement from Clinomics regarding the determination of the first issue price for a paid-in capital increase (rights offering). It details the number of shares, the calculated price per share, and the methodology for determining the final issue price. This falls under the category of capital and financing updates, specifically related to share issuance and capital structure changes.
2023-06-26 Korean
[기재정정]주요사항보고서(유무상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Report' (주요사항보고서) regarding a decision on capital increase (유무상증자결정), specifically a correction (정정신고) to a previously filed report. It details the purpose of funds, issuance price, and allocation methods for both paid-in and bonus capital increases. This falls under the category of announcements regarding new share issues and capital structure changes.
2023-06-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.